SHMN

SOHM, Inc. is a pharmaceutical, cosmeceutical and nutraceutical and biotech manufacturer that produces and markets generic drugs and products for all major treatment categories. The Company is focused on developing, manufacturing and distributing generic, branded generic, private label pharmaceuticals, cosmeceuticals and nutraceutical products. The Company’s products include Omega-3 with EPA, DHA & Vitamin D3, I-Prolec, Various Gummies, Levetiracetam, Hydroquinone USP, 4%, Sodium Sulfacetamide 10% Sulfur 2%, Sodium Sulfacetamide 9.8% Sulfur 4.8%, Sodium Sulfacetamide 10% Sulfur 5%, Nail Renovar, and Fohm by SOHM. The Company’s generic pharmaceuticals are exported globally with a focus on distribution in markets in Africa, Latin America, and Southeast Asia. It has also acquired the intellectual property portfolio entitled Cas 9 retroviral integrase and Cas 9 recombinase systems for targeted incorporation of a DNA sequence into a genome of a cell or organism.